Hutchison China Meditech Ltd (HCM)

13.89
0.06 0.43
NASDAQ : Health Care
Prev Close 13.83
Open 14.00
Day Low/High 13.51 / 14.00
52 Wk Low/High 9.80 / 14.70
Volume 8.98K
Avg Volume 36.80K
Exchange NASDAQ
Shares Outstanding 120.57M
Market Cap 1.67B
EPS -0.30
Div & Yield N.A. (N.A)

Latest News

Chi-Med Initiates A Phase II Study Of Sulfatinib In Second-line Biliary Tract Cancer In China

Chi-Med Initiates A Phase II Study Of Sulfatinib In Second-line Biliary Tract Cancer In China

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer ("BTC") patients in China.

Chi-Med Initiates A Phase II Combination Study Of Fruquintinib With Iressa® (gefitinib) In First-Line Non-Small Cell Lung Cancer

Chi-Med Initiates A Phase II Combination Study Of Fruquintinib With Iressa® (gefitinib) In First-Line Non-Small Cell Lung Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa ® in the first-line setting for patients with...

Chi-Med Initiates HMPL-523 Clinical Trials In Hematological Cancer In China

Chi-Med Initiates HMPL-523 Clinical Trials In Hematological Cancer In China

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase ("Syk") inhibitor, HMPL-523, in patients with hematological...

Chi-Med Presents Pre-clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 American Society Of Hematology Annual Meeting

Chi-Med Presents Pre-clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 American Society Of Hematology Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities of novel Spleen Tyrosine Kinase...

Chi-Med To Present Data From Proof-of-Concept Clinical Trials For Fruquintinib And Epitinib At The 17th World Conference On Lung Cancer (

Chi-Med To Present Data From Proof-of-Concept Clinical Trials For Fruquintinib And Epitinib At The 17th World Conference On Lung Cancer ("WCLC")

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that results from two non-small cell lung cancer ("NSCLC") clinical studies will be presented at WCLC in Vienna, Austria, from December 4 to 7,...

Chi-Med Webcast Presentation Now Available For On-demand Viewing: Deutsche Bank ADR Virtual Investor Conference

Chi-Med Webcast Presentation Now Available For On-demand Viewing: Deutsche Bank ADR Virtual Investor Conference

Chi-Med invites individual and institutional investors, as well as advisors, to log-on to view the presentation

Chi-Med Presents Phase I Clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 ACR/ARHP Annual Meeting

Chi-Med Presents Phase I Clinical Data For Selective Syk Inhibitor HMPL-523 At The 2016 ACR/ARHP Annual Meeting

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokinetics ("PK") and...

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

Chi-Med Commercial Platform Joint Venture Receives US$59.5 Million Land Compensation Payment

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its 50:50 Prescription Drug joint venture with a subsidiary of Shanghai Pharmaceuticals...

ZTO Express, One of Alibaba's Largest Shippers, Has Great Timing For U.S. Listing

ZTO Express, One of Alibaba's Largest Shippers, Has Great Timing For U.S. Listing

The company that ships packages for Jack Ma's e-commerce giant is ready to follow suit with a public listing in the U.S.

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.

Hutchison China MediTech Limited (

Hutchison China MediTech Limited ("Chi-Med"): Change Of Non-executive Directors

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place of Mr Salbaing who has tendered...

Hutchison China MediTech Limited (

Hutchison China MediTech Limited ("Chi-Med") Reports Interim Results For The Six Months Ended June 30, 2016, Provides 2016 Financial Guidance And Updates Shareholders On Key Clinical Programs

Chi-Med (AIM/NASDAQ: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market, today announces its unaudited...

Chi-Med And AstraZeneca Amend Co-development Agreement To Accelerate Savolitinib Global Development Program

Chi-Med And AstraZeneca Amend Co-development Agreement To Accelerate Savolitinib Global Development Program

Chi-Med and AstraZeneca today announced an amendment (the "Amendment") to the 2011 global licensing, co-development, and commercialisation agreement (the "2011 Agreement") regarding savolitinib.

Chi-Med Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib In Colorectal Cancer

Chi-Med Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib In Colorectal Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced or...

Chi-Med To Participate In Two Healthcare Investor Conferences In May

Chi-Med To Participate In Two Healthcare Investor Conferences In May

Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that Chief Executive Officer Christian Hogg will present a corporate overview at two healthcare investor conferences in May.

Hutchison China MediTech Limited Announces Exercise Of Overallotment Option

Hutchison China MediTech Limited Announces Exercise Of Overallotment Option

Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares ("ADSs") on the Nasdaq Global Select Market (the "Offering") have exercised their...

Chi-Med Initiates First-in-Human Clinical Trial Of Novel PI3K Inhibitor HMPL-689

Chi-Med Initiates First-in-Human Clinical Trial Of Novel PI3K Inhibitor HMPL-689

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the first-in-human ("FIH") Phase I clinical trial of...

Hutchison China MediTech Limited Announces Closing Of U.S. Public Offering Of ADSs Raising Approximately US$101 Million On The Nasdaq Stock Market

Hutchison China MediTech Limited Announces Closing Of U.S. Public Offering Of ADSs Raising Approximately US$101 Million On The Nasdaq Stock Market

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the closing of its U.

Chi-Med Initiates Sulfatinib Phase III Registration Study In Pancreatic Neuroendocrine Tumor Patients

Chi-Med Initiates Sulfatinib Phase III Registration Study In Pancreatic Neuroendocrine Tumor Patients

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of sulfatinib...

Hutchison China MediTech Limited Announces Pricing Of U.S. Public Offering Of ADSs

Hutchison China MediTech Limited Announces Pricing Of U.S. Public Offering Of ADSs

Hutchison China MediTech Limited ("Chi-Med") (AIM:HCM) announces the pricing of its U.

Hanover Capital Delays Filing

The company cites conditions in the mortgage market.